S4E1: New RNA platform can predict pregnancy complications

Podcast

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Subscribe Now!
Recent Videos
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Ivie Odiase, MD
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Laxmi Gannu, MD, notes PPD screening gaps and adverse outcomes | Image Credit: linkedin.com.
Farah Amro, MD
Laurence Shields, MD, is System Physician Vice President at the Women and Infants Clinical Institute with CommonSpirit Health in Santa Maria, California.
Joy Baker, MD, FACOG, highlights how to recognize PPD | Image Credit: linkedin.com.
Related Content
Q2 Recap: What's new in obstetrics and gynecology? | Image Credit: © oatawa - stock.adobe.com.

Q2 Recap: What's new in obstetrics and gynecology?

Morgan Ebert, Managing Editor
July 2nd 2025
Article

Take a quick look at everything you may have missed during Q2 of 2025, including the latest FDA approvals, top stories, and exclusive interviews.

Read More

Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 2

Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 2

Lindsey Carr, Editor
December 22nd 2022
Podcast

This is part 2 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.

Listen

CDC COVID-19 vaccine policy reversal raises alarms for pregnant women | Image Credit: © myskin - © myskin - stock.adobe.com.

CDC COVID-19 vaccine policy reversal raises alarms for pregnant women

Celeste Krewson, Assistant Editor
June 30th 2025
Article

Experts warn that removing the COVID-19 vaccine from CDC guidelines endangers maternal and neonatal health and undermines evidence-based medical practice.

Read More

Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 1

Bonus episode: Alternatives to hysterectomy & uterine-preserving options for fibroids, part 1

Lindsey Carr, Editor
December 21st 2022
Podcast

This is part 1 of a 2-part series. In this bonus episode of Pap Talk, get an exclusive recap of Kimberly Kho, MD's presentation from AAGL 2022 on alternatives to hysterectomy and uterine-preserving options for fibroids.

Listen

Rising postpartum hemorrhage linked to higher costs and SMM | Image Credit: © Meeko Media - © Meeko Media - stock.adobe.com.

Rising postpartum hemorrhage linked to higher costs and SMM

Celeste Krewson, Assistant Editor
June 25th 2025
Article

A new study reveals that abnormal postpartum bleeding is more common than previously reported, driving up hospital costs and increasing the risk of serious complications.

Read More

Oral sulopenem demonstrates non-inferiority to amoxicillin/clavulanate in phase 3 uUTI trial | Image Credit: © valiantsin - stock.adobe.com.

Oral sulopenem demonstrates non-inferiority to amoxicillin/clavulanate in phase 3 uUTI trial

Morgan Ebert, Managing Editor
June 25th 2025
Article

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

Read More

© 2025 MJH Life Sciences

All rights reserved.